Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

PURPOSE: Evolocumab significantly reduces low-density lipoprotein-cholesterol (LDL-C); we investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. METHODS: We compared the efficacy and safety of evolocumab in hypercholesterolemic patients selected from the phase 2 and 3 tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenson, Robert S., Jacobson, Terry A., Preiss, David, Djedjos, C. Stephen, Dent, Ricardo, Bridges, Ian, Miller, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919379/
https://www.ncbi.nlm.nih.gov/pubmed/27240673
http://dx.doi.org/10.1007/s10557-016-6666-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919379/
https://www.ncbi.nlm.nih.gov/pubmed/27240673
http://dx.doi.org/10.1007/s10557-016-6666-1

Ejemplares similares